Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor. Patients diagnosed with GBM have a poor prognosis, and it has been reported that tumor malignancy and GBM recurrence are promoted by STAT3 signaling. As resveratrol (RV), a polyphenol in grapes, is reported to be a potent and non‐toxic cancer‐preventive compound, the aim of this study was to investigate the therapeutic effect and molecular mechanisms of RV on GBM‐derived radioresistant tumor initiating cells (TIC). Firstly, our results showed that primary GBM‐CD133+ TIC presented high tumorigenic and radiochemoresistant properties as well as increased protein levels of phosphorylated STAT3. We consistently observed that treatment with shRNA‐STAT3 (sh‐STAT3) or AG490, a STAT3 inhibitor, significantly inhibited the cancer stem‐like cell properties and radioresistance of GBM‐CD133+ in vitro and in vivo. Furthermore, treatment of GBM‐CD133+ with 100 µM RV induced apoptosis and enhanced radiosensitivity by suppressing STAT3 signaling. Microarray results suggested that RV or AG490 inhibited the stemness gene signatures of GBM‐CD133+ and facilitated the differentiation of GBM‐CD133+ into GBM‐CD133− or astrocytoma cells. Finally, xenotransplant experiments indicated that RV or sh‐STAT3 therapy could significantly improve the survival rate and synergistically enhance the radiosensitivity of radiation‐treated GBM‐TIC. In summary, RV can reduce in vivo tumorigenicity and enhance the sensitivity of GBM‐TIC to radiotherapies through the STAT3 pathway. J. Cell. Physiol. 227: 976–993, 2012. © 2011 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 2×
“The role of STAT3 in tumorigenesis is to mediate the expression of downstream genes that suppress apoptosis, regulate cell cycle progression, mediate cellular invasion, and modulate angiogenesis (Yu and Jove, 2004).”
BackgroundBowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743 · cited 1×
“…(STAT), a transcription factor for cytokine signaling, is constitutively activated in numerous cancer types, including prostate cancer, breast cancer, leukemia, multiple myeloma, nasopharyngeal carcinoma, and brain tumors (Bowman et al., 2000; Bromberg, 2001, 2002; Epling-Burnette et al., 2001).”
BackgroundEpling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci9940 · Cited by 633 · cited 1×
“…(STAT), a transcription factor for cytokine signaling, is constitutively activated in numerous cancer types, including prostate cancer, breast cancer, leukemia, multiple myeloma, nasopharyngeal carcinoma, and brain tumors (Bowman et al., 2000; Bromberg, 2001, 2002; Epling-Burnette et al., 2001).”
BackgroundBhardwaj, A., Sethi, G., Vadhan-Raj, Bueso-Ramos, C., Takada, Y., Gaur, U., Nair, A. S., Shishodia, S., & Aggarwal, B. B. (2007) · Blood · doi:10.1182/blood-2006-02-003988 · Cited by 395
Rahaman, S. O., Harbor, P. C., Chernova, O., Barnett, G. H., Vogelbaum, M. A., & Haque, S. J. (2002) · Oncogene · doi:10.1038/sj.onc.1206047 · Cited by 377 · cited 1×
“Recent studies have demonstrated that inhibition of the STAT3-mediated signaling pathway reduces tumor growth, invasiveness, and migration of GBM cell lines (Rahaman et al., 2002; Li et al., 2009; Senft et al., 2011).”
Background
Cited by
Kim, E., Kim, M., Woo, D.-H., Shin, Y., Shin, J., Chang, N., Oh, Y. T., Kim, H., Rheey, J., Nakano, I., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.008 · Cited by 806
Therapeutic modulators of STAT signalling for human diseases
Miklossy, G., Hilliard, T. S., & Turkson, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4088 · Cited by 413
Role of STAT3 in Cancer Metastasis and Translational Advances
Kamran, M. Z., Patil, P., & Gude, R. P. (2013) · BioMed Research International · doi:10.1155/2013/421821 · Cited by 393
Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma
Jhaveri, A., Deshpande, P., Pattni, B., & Torchilin, V. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.03.006 · Cited by 294
McCubrey, J. A., Lertpiriyapong, K., Steelman, L. S., Abrams, S. L., Yang, L. V., Murata, R. M., Rosalen, P. L., Scalisi, A., Neri, L. M., Cocco, L., et al. (2017) · Aging · doi:10.18632/aging.101250 · Cited by 285
Cancer Stem Cell Hierarchy in Glioblastoma Multiforme
Bradshaw, A., Wickremsekera, A., Tan, S. T., Peng, L., Davis, P. F., & Itinteang, T. (2016) · Frontiers in Surgery · doi:10.3389/fsurg.2016.00021 · Cited by 258
Cancer stem cells: In the line of fire
Alison, M. R., Lin, W.-R., Lim, S. M. L., & Nicholson, L. J. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.03.003 · Cited by 225
“Using a Wee-1 kinase inhibitor, it was possible to sensitise glioblastoma cells to irradiation.31 A number of other pathways have been implicated in the radioresistance of brain CSCs.”
BackgroundInfluentialNatural polyphenols in cancer therapy
Asensi, M., Ortega, A., Mena, S., Feddi, F., & Estrela, J. M. (2011) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.631268 · Cited by 174
Resveratrol Brain Delivery for Neurological Disorders Prevention and Treatment
Andrade, S., Ramalho, M. J., Pereira, M. D. C., & Loureiro, J. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01261 · Cited by 173
STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo
Spitzner, M., Roesler, B., Bielfeld, C., Emons, G., Gaedcke, J., Wolff, H. A., Rave‐Fränk, M., Kramer, F., Beissbarth, T., Kitz, J., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28429 · Cited by 128
“Similar findings have been subsequently reported for A431 squamous cell carcinomas cells,(39) glioma cells,(40) head and neck squamous cell carcinoma cells(41) and glioblastoma tumor-initiating cells.(42) Our results add weight to the growing body of evidence that STAT3 inhibition may represent a potential strategy fo…”
Result
Metadata
- Authors
- Yang, Y., Chang, Y., Huang, P., Chiou, G., Tseng, L., Chiou, S., Chen, M., Chen, M., Shih, Y., Chang, C., Hsu, C., Ma, H., Wang, C., Tsai, L., Yu, C., & Chang, C.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2011-12-22
- Volume
- 227
- Issue
- 3
- Pages
- 976-993
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2063827609
- Cited by
- 139
- References
- 5
- FWCI
- 6.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.